The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

In my last column about the Novo Nordisk Foundation, I wrote about the company’s efforts in anti-microbial resistance, an example of an area where impact investment was necessary to combat ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner last year (A$64 billion) — up 25%. Novo Nordisk boasts 45 million ...

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...